Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Tandem Diabetes Care Inc (NASDAQ: TNDM) closed the day trading at $21.35 down -1.61% from the previous closing price of $21.7. In other words, the price has decreased by -$1.61 from its previous closing price. On the day, 1.25 million shares were traded. TNDM stock price reached its highest trading level at $22.135 during the session, while it also had its lowest trading level at $21.15.
Ratios:
For a better understanding of TNDM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 2.44. In the meantime, Its Debt-to-Equity ratio is 3.38 whereas as Long-Term Debt/Eq ratio is at 3.22.
On September 08, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $22.Oppenheimer initiated its Outperform rating on September 08, 2025, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Sheridan John F bought 10,000 shares for $10.23 per share. The transaction valued at 102,318 led to the insider holds 106,327 shares of the business.
Vosseller Leigh bought 13,720 shares of TNDM for $149,404 on Aug 08 ’25. The EVP & CHIEF FINANCIAL OFFICER now owns 25,580 shares after completing the transaction at $10.89 per share. On Mar 07 ’25, another insider, Kyrillos Jean-Claude, who serves as the EVP & Chief Operating Officer of the company, bought 10,538 shares for $18.12 each. As a result, the insider paid 190,966 and bolstered with 10,538 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNDM now has a Market Capitalization of 1447580416 and an Enterprise Value of 1582653312. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.44 while its Price-to-Book (P/B) ratio in mrq is 10.88. Its current Enterprise Value per Revenue stands at 1.572 whereas that against EBITDA is -22.745.
Stock Price History:
The Beta on a monthly basis for TNDM is 1.69, which has changed by -0.3936854 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, TNDM has reached a high of $37.93, while it has fallen to a 52-week low of $9.98. The 50-Day Moving Average of the stock is 6.34%, while the 200-Day Moving Average is calculated to be 23.27%.
Shares Statistics:
Over the past 3-months, TNDM traded about 1.95M shares per day on average, while over the past 10 days, TNDM traded about 1146320 shares per day. A total of 67.77M shares are outstanding, with a floating share count of 67.10M. Insiders hold about 1.03% of the company’s shares, while institutions hold 114.28% stake in the company. Shares short for TNDM as of 1767139200 were 8544303 with a Short Ratio of 4.38, compared to 1764288000 on 8753315. Therefore, it implies a Short% of Shares Outstanding of 8544303 and a Short% of Float of 17.44.
Earnings Estimates
The stock of Tandem Diabetes Care Inc (TNDM) is currently in the spotlight, with 20.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.2 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.5 and -$3.32 for the fiscal current year, implying an average EPS of -$2.16. EPS for the following year is -$0.98, with 22.0 analysts recommending between -$0.58 and -$2.39.
Revenue Estimates
19 analysts predict $277.14M in revenue. The current quarter. It ranges from a high estimate of $281.86M to a low estimate of $272.2M. As of. The current estimate, Tandem Diabetes Care Inc’s year-ago sales were $282.65MFor the next quarter, 19 analysts are estimating revenue of $248.83M. There is a high estimate of $261.4M for the next quarter, whereas the lowest estimate is $232.28M.
A total of 23 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $1.01B, while the lowest revenue estimate was $996.5M, resulting in an average revenue estimate of $1B. In the same quarter a year ago, actual revenue was $940.2MBased on 23 analysts’ estimates, the company’s revenue will be $1.1B in the next fiscal year. The high estimate is $1.14B and the low estimate is $1.07B.
